Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis

Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4−/− Mice

(2017) Marica Cariello et al.   Scientific Reports

The FXR-FGF19 Gut–Liver Axis as a Novel “Hepatostat”

(2015) Matias A. Avila et al.   GASTROENTEROLOGY

Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers

(2015) Willscott E. Naugler et al.   GASTROENTEROLOGY

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2 -deficient mice

(2015) Mei Zhou et al.   HEPATOLOGY

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19

(2014) M. Zhou et al.   CANCER RESEARCH

Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation

(2014) Chiara Degirolamo et al.   HEPATOLOGY

A nontumorigenic variant of FGF19 treats cholestatic liver diseases

(2014) J. Luo et al.   Science Translational Medicine

Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM

(2013) Yoh Zen et al.   HISTOPATHOLOGY

Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice

(2013) Guodong Li et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice

(2012) Bo Kong et al.   HEPATOLOGY

Hepatocarcinogenesis in FXR−/−Mice Mimics Human HCC Progression That Operates through HNF1α Regulation of FXR Expression

(2012) Nian Liu et al.   MOLECULAR ENDOCRINOLOGY

Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

(2012) Dorothy M. French et al.   PLoS One

Regulation of Amphiregulin Gene Expression by β-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System

(2012) Maria U. Latasa et al.   PLoS One

Antibody-Mediated Inhibition of Fibroblast Growth Factor 19 Results in Increased Bile Acids Synthesis and Ileal Malabsorption of Bile Acids in Cynomolgus Monkeys

(2012) Rama Pai et al.   TOXICOLOGICAL SCIENCES

Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening

(2011) Eric T. Sawey et al.   CANCER CELL

Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis

(2011) Salvatore Modica et al.   GASTROENTEROLOGY

FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis

(2011) S. Kir et al.   SCIENCE

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Central Role of c-Myc during Malignant Conversion in Human Hepatocarcinogenesis

(2009) P. Kaposi-Novak et al.   CANCER RESEARCH

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression

(2008) Kwang-Hoon Song et al.   HEPATOLOGY

High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis

(2008) Frank G. Schaap et al.   HEPATOLOGY

Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation

(2008) Yuxia Zhang et al.   HEPATOLOGY